Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
04 January 2022 - 8:30AM
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a
clinical stage biopharmaceutical company focused on developing its
proprietary technology to harness the power of the immune system to
combat cancer, today announced that Alan Fuhrman, Interim CEO
and President, will present at the H.C. Wainwright BioConnect
Virtual Conference being held on January 10-13, 2022. The
pre-recorded webcast will be available on-demand starting on
Monday, January 10 at 7:00am ET. Checkmate will also host 1x1
investor meetings during the conference.
About Checkmate Pharmaceuticals
Checkmate Pharmaceuticals is a clinical stage biotechnology
company focused on developing its proprietary technology to harness
the power of the immune system to combat cancer. Checkmate
Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an
advanced generation Toll-like receptor 9 (TLR9) agonist, delivered
as a biologic virus-like particle utilizing a CpG-A
oligodeoxynucleotide as a key component, designed to trigger the
body’s innate immune system to attack tumors in combination with
other therapies. Information regarding Checkmate Pharmaceuticals is
available at www.checkmatepharma.com.
Availability of Other Information About Checkmate
Pharmaceuticals
Investors and others should note that we communicate with our
investors and the public using our website
(www.checkmatepharma.com), our investor relations website
(ir.checkmatepharma.com), and on social media (Twitter and
LinkedIn), including but not limited to: investor presentations and
investor fact sheets, U.S. Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Checkmate Pharmaceuticals posts on these channels
and websites could be deemed to be material information. As a
result, we encourage investors, the media, and others interested in
us to review the information that is posted on these channels,
including the investor relations website, on a regular basis. This
list of channels may be updated from time to time on our investor
relations website and may include additional social media channels.
The contents of our website or these channels, or any other website
that may be accessed from our website or these channels, shall not
be deemed incorporated by reference in any filing under the
Securities Act of 1933.
Forward Looking Statements
Various statements in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including words such as, but not
limited to, “anticipate,” “believe,” “can,” “could,” “expect,”
“estimate,” “design,” “goal,” “intend,” “may,” “might,”
“objective,” “plan,” “predict,” “project,” “target,” “likely,”
“should,” “will,” and “would,” or the negative of these terms and
similar expressions or words, identify forward-looking statements.
Forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions, and
uncertainties. These statements include those regarding vidutolimod
(CMP-001), including its development and therapeutic potential and
the advancement of our clinical and preclinical pipeline;
expectations regarding the results and analysis of data; and
expectations regarding the timing, initiation, implementation and
success of its planned and ongoing clinical trials for vidutolimod
and the benefits and related implications of current and future
partnerships and/or collaborations; and expectations regarding the
Company’s use of capital, expenses and other financial results.
Forward-looking statements should not be read as a guarantee of
future performance or results and may not be accurate indications
of when such performance or results will be achieved. These
forward-looking statements are subject to risks and uncertainties,
including those related to the development of our product
candidate, including any delays in our ongoing or planned
preclinical or clinical trials, the results from clinical trials,
including the fact that positive results from a trial may not
necessarily be predictive of the results of future or ongoing
clinical trials, the impact of the ongoing COVID-19 pandemic on our
business, operations, clinical supply and plans, the risks inherent
in the drug development process, the risks regarding the accuracy
of our estimates of expenses and timing of development, our capital
requirements and the need for additional financing, and obtaining,
maintaining and protecting our intellectual property. These and
additional risks are discussed in the sections titled “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in our Quarterly Report on
Form 10-Q for the nine months ended September 30, 2021 and in our
Annual Report on Form 10-K for the year ending December 31, 2020,
as filed with the Securities and Exchange Commission which are
available on the Securities and Exchange Commission’s website at
www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in our subsequent filings
with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and Checkmate
undertakes no duty to update this information unless required by
law.
Investor Contact
Rob Dolski
Chief Financial Officer
rdolski@checkmatepharma.com
Media Contact
Karen Sharma
MacDougall Advisors
781-235-3060
ksharma@macdougall.bio
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Checkmate Pharmaceuticals (NASDAQ:CMPI)
Historical Stock Chart
From Jul 2023 to Jul 2024